286 related articles for article (PubMed ID: 28394433)
1. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
2. Oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization: A pediatric experience.
Diachinsky M; Tran T; Jupp J; McKinnon K
J Oncol Pharm Pract; 2021 Jan; 27(1):119-127. PubMed ID: 32316877
[TBL] [Abstract][Full Text] [Related]
3. Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.
Kintzel PE; Campbell AD; Yost KJ; Brinker BT; Arradaza NV; Frobish D; Wehr AM; O'Rourke TJ
J Oncol Pharm Pract; 2012 Jun; 18(2):239-44. PubMed ID: 22075004
[TBL] [Abstract][Full Text] [Related]
4. Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate.
Clemmons AB; Chase A; Duong P; Waller JL; Saunders K; Bryan L
Support Care Cancer; 2021 Mar; 29(3):1527-1534. PubMed ID: 32725375
[TBL] [Abstract][Full Text] [Related]
5. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of methotrexate clearance with an enteral urine alkalinization protocol for patients receiving high-dose methotrexate.
Kramer E; Filtz M; Pace M
J Oncol Pharm Pract; 2021 Jan; 27(1):26-32. PubMed ID: 32164493
[TBL] [Abstract][Full Text] [Related]
7. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
8. Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage.
Visage R; Kaiser N; Williams M; Kim A
J Pediatr Hematol Oncol; 2019 Jul; 41(5):371-375. PubMed ID: 30475303
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
10. Effect of urine pH and flow on renal clearance of methotrexate.
Sand TE; Jacobsen S
Eur J Clin Pharmacol; 1981; 19(6):453-6. PubMed ID: 7250179
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of sodium acetate use for urine alkalinization in patients receiving high dose methotrexate.
Perkey CL; Flynn LA; Lentz K; Butler S
J Oncol Pharm Pract; 2023 Jan; 29(1):119-124. PubMed ID: 34931924
[TBL] [Abstract][Full Text] [Related]
12. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
13. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
14. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
[TBL] [Abstract][Full Text] [Related]
15. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
16. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
Chen AR; Wang YM; Lin M; Kuo DJ
Cureus; 2020 Jun; 12(6):e8674. PubMed ID: 32699674
[TBL] [Abstract][Full Text] [Related]
17. [Survey of Methotrexate Prescription and Blood Concentration in Patients Treated with High-Dose Methotrexate].
Kobayashi S; Yasu T; Momo K; Ohno N
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1063-1067. PubMed ID: 32668853
[TBL] [Abstract][Full Text] [Related]
18. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
19. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
[TBL] [Abstract][Full Text] [Related]
20. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]